CONCORDBIO - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.0
✅ Positive
The stock has shown significant earnings growth over the past two quarters with PAT increasing from 70.2 Cr to 90.0 Cr, indicating improving profitability. Furthermore, the recent increase in DII holdings suggests growing investor interest.
⚠️ Limitation
Despite the positive earnings trend, the stock is trading at a high P/E ratio of 61.6 and a PEG Ratio of 80.0, suggesting overvaluation. The “Sell” rating from Markets Mojo introduces substantial downside risk.
📉 Company Negative News
Markets Mojo has assigned a "Sell" rating to Concord Biotech, reflecting concerns about the company's performance and outlook.
📈 Company Positive News
The stock recently hit 52-week highs across several other companies including Gujarat Gas, Hindustan Petroleum, Bajaj Finserv, Godrej Industries and Bikaji Foods.
🏭 Industry
The biotechnology sector in India is experiencing growth driven by increasing healthcare spending and government initiatives. However, competition within the industry remains intense and valuations are often high, particularly for smaller biotech firms.
🧾 Conclusion
Based on the current price of 1,420 ₹, a potential entry zone could be between 1,380 ₹ (support level) and 1,410 ₹ (resistance), utilizing the DMA 50 and 200 moving averages as dynamic support/resistance. The stock appears to be trending upwards currently, but the “Sell” rating warrants caution, suggesting an exit strategy should be implemented if the price breaches the 1,380 ₹ level or if the RSI drops below 50, resulting in a neutral-to-negative outlook.